A number of research firms have changed their ratings and price targets for Zynerba Pharmaceuticals (NASDAQ: ZYNE):

  • 8/15/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Jefferies Group LLC from a “buy” rating to a “hold” rating. They now have a $7.00 price target on the stock, down previously from $12.00.
  • 8/15/2017 – Zynerba Pharmaceuticals was given a new $7.00 price target on by analysts at HC Wainwright. They now have a “hold” rating on the stock.
  • 8/15/2017 – Zynerba Pharmaceuticals was upgraded by analysts at Roth Capital from a “neutral” rating to a “buy” rating. They now have a $15.00 price target on the stock.
  • 8/15/2017 – Zynerba Pharmaceuticals had its “market perform” rating reaffirmed by analysts at CIBC.
  • 8/14/2017 – Zynerba Pharmaceuticals had its “hold” rating reaffirmed by analysts at Maxim Group.
  • 8/14/2017 – Zynerba Pharmaceuticals was given a new $4.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 8/14/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Oppenheimer Holdings, Inc. from an “outperform” rating to a “market perform” rating.
  • 8/10/2017 – Zynerba Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. “
  • 8/9/2017 – Zynerba Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $12.00 price target on the stock, down previously from $32.00.
  • 8/8/2017 – Zynerba Pharmaceuticals was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $7.00 price target on the stock, down previously from $30.00.
  • 8/8/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Roth Capital from a “buy” rating to a “neutral” rating. They now have a $7.00 price target on the stock, down previously from $30.00.
  • 8/8/2017 – Zynerba Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
  • 8/7/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating. They now have a $7.00 price target on the stock, down previously from $42.00.
  • 8/7/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating. They now have a $4.00 price target on the stock, down previously from $28.00.
  • 8/7/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating.
  • 8/7/2017 – Zynerba Pharmaceuticals was given a new $8.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/7/2017 – Zynerba Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 8/4/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. “
  • 8/1/2017 – Zynerba Pharmaceuticals was given a new $30.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/1/2017 – Zynerba Pharmaceuticals was given a new $32.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 8/1/2017 – Zynerba Pharmaceuticals was given a new $28.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/13/2017 – Zynerba Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. “
  • 7/12/2017 – Zynerba Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/9/2017 – Zynerba Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $32.00 price target on the stock.
  • 6/26/2017 – Zynerba Pharmaceuticals was given a new $32.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.

Zynerba Pharmaceuticals, Inc. (ZYNE) traded up 1.92% on Wednesday, reaching $6.36. The company’s stock had a trading volume of 1,673,477 shares. Zynerba Pharmaceuticals, Inc. has a one year low of $5.42 and a one year high of $25.95. The stock has a 50-day moving average of $15.26 and a 200-day moving average of $18.90. The stock’s market cap is $84.31 million.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.04. On average, analysts predict that Zynerba Pharmaceuticals, Inc. will post ($2.45) EPS for the current fiscal year.

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Receive News & Ratings for Zynerba Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.